For the quarter ended March 2025, Sarepta Therapeutics (SRPT) reported revenue of $744.86 million, up 80.2% over the same period last year. EPS came in at -$3.42, compared to $0.73 in the year-ago quarter.
The reported revenue represents a surprise of +6.68% over the Zacks Consensus Estimate of $698.2 million. With the consensus EPS estimate being $0.35, the EPS surprise was -1077.14%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $611.52 million versus the nine-analyst average estimate of $663.98 million. The reported number represents a year-over-year change of +70.1%.
- Revenues- Collaboration: $133.33 million versus $32.75 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +147% change.
- Revenues- PMO Products: $236.54 million versus the eight-analyst average estimate of $233.14 million.
- Revenues- Product, net- ELEVIDYS: $374.99 million compared to the $425.16 million average estimate based on eight analysts.
View all Key Company Metrics for Sarepta Therapeutics here>>>
Shares of Sarepta Therapeutics have returned +21.5% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
